**VNR – % din valoarea nutrițională de referință
1,5 µg = 60 UI
0,25 ml (7-8 picături) soluţie o dată pe zi, în timpul mesei.
Agitaţi bine sticla înainte de fiecare folosire până când soluţia este omogenă.
Se poate administra din prima zi de viaţă!
Susține proliferarea celulară
Reduce oboseala și senzația de slăbiciune
Crește energia, susține proliferarea celulară
Metabolism energetic normal
Contribuie la funcționarea normală a sistemului nervos
Contribuie la menținerea sănătății pielii
Cutie cu 7 flacoane x 7 ml.
Administrare 1 flacon/zi
În cazul administrării antibioticelor, se recomandă administrarea separată a antibioticului și Lactoflora® protecţie intestinală pentru copii la un interval de cel puțin 2 ore.
1.CHRISTOPHER J. STEWART. Temporal development of the gut microbiome in early childhood from the TEDDY study. Naturereseacrch jurnal. 2018
2..Turroni, F. et al. (2012) Diversity of Bifidobacteria within the infant gut microbiota. PLoS ONE
3.BJÖRKSTÉN B1. Allergy development and the intestinal microflora during the first year of life. J Allergy Clin Immunol. 2001
4.Neu J., Rushing J., Cesarean versus vaginal delivery: long-term infant outcomes and the hygiene hypothesis; Clinics Perinatology, 2011 Jun;38(2):321-31
5.Amy Langdon et. al, The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulation, Genome Med 2016 Apr 13;8(1):39
6.Fedica Guaraldi, G Salvatori, Effect of Breast and Formula Feeding on Gut, Microbiota Shaping in Newborns, Front Cell Infect Microbiol. 2012 Oct
7.R. Balamurugan et al, Molecular Studies of Fecal Anaerobic Commensal Bacteria in Acute Diarrhea in Children, J Pediatr Gastroenterol Nutr. 2008 May;46(5):514-9
8.Lawrence A. David et al, Diet rapidly and reproducibly alters the human gut microbiome, Nature 2014 Jan 23;505(7484):559-63
9.Hatakka et al. 2001, Hojsak et al. 2010a, Hojsak et al. 2010b 2. Pärtty et al. 2013 3. Kirjavainen, 2003, 4. Szajewska et al, 2016 5. Szajewska H et al. 2014 6. Hojsak et al, 2018
10.TaipaleT, PienihäkkinenK, IsolauriE, et al. Bifidobacteriumanimalisssp. lactis, BB-12 in reducingtherisk ofinfectionsin infancy. Br J Nutr. 2011; 105(3): 409–416.
11. Bendali F, Madi N, Sadoun D. Beneficial effects of a strain of Lactobacillus paracasei subsp. paracasei in Staphylococcus aureus-induced
intestinal and colonic injury. Int J Infect Dis. 2011 Nov;15(11):e787-94.
12. Chiang SS, Pan TM. Beneficial effects of Lactobacillus paracasei subsp. paracasei NTU 101 and its fermented products. Appl Microbiol Biotechno. 2012 Feb;93(3):903- 16.
13.Danisco. Lactobacillus paracasei Lpc-37 probiotic identity card.
https://www.fda.gov/files/food/published/GRAS-Notice-GRN-736-Lactobacillus-casei-subsp-paracasei-Lpc-37.pdf
14. Lewis MC, Patel DV, Fowler J, Duncker S, Zuercher AW, Mercenier A, Bailey M. Dietary supplementation with Bifidobacterium lactis NCC2818 from weaning reduces local immunoglobulin production in lymphoid-associated tissues but increases systemic antibodies in healthy neonates. Br J Nutr. 2013 Oct;110(7):1243-52.
15. Schoster A, Kokotovic B, Permin A, Pedersen PD, Bello FD, Guarabassi L. In vitro inhibition of Clostridium difficile and Clostridium perfringens by commercial probiotic strains. Anaerobe. 2013 Apr; 20:36-41
16. Ouwehand AC, DongLian C, Weijian X, Stewart M, Ni J, Stewart T, et al. Probiotics reduce symptoms of antibiotic use in a hospital setting: a
randomized dose response study. Vaccine. 2014 Jan 16;32(4):458–63.
17.Paineau, D., Carcano, D., Leyer, G.,Darquy, S., Alyanakian, M.A., Simoneau, G., Bergmann, J.F., Brassart, D., Bornet, F. & Ouwehand, A.C. (2008). Effects of seven potential probiotic strains on specific immune responses in healthy adults: a double-blind, randomized, controlled trial. FEMS Immunology & Medical Microbiology 53 (1), 107–113.
18.Schrezenmeir et all, Benefits of Oral Supplementation With and Without Synbiotics inYoung Children With Acute Bacterial Infections.Clinical Pediatrics 43;239-249
19. Ouwehand, A., Leyer, G. & Carcano,D. (2008). Probiotics reduce incidence and duration of respiratory tract infection symptoms in 3-to 5- year-old
children. Pediatrics 121;S115 (abstr.)
20. Reid, G. (2000). Investigation of the properties of Lactobacillus acidophilus NCFM™ as a possible probiotic for the urogenital tract. International Dairy Journal 10, (5-6): 415-419.